Lisata Therapeutics announces a one-for-fifteen reverse stock split, effective November 23, 2026, reducing outstanding shares significantly.
Quiver AI Summary
Lisata Therapeutics, Inc. announced a one-for-fifteen reverse stock split of its common stock, which will take effect on November 23, 2026. This decision follows approval from stockholders at the company's annual meeting on November 9, 2026. As a result of the split, the number of outstanding shares will decrease from approximately 10.8 million to about 0.7 million shares, while each stockholder's percentage ownership will remain mostly unchanged, except for minor adjustments related to fractional shares. Stockholders with fractional shares will receive a cash payment based on the closing price of the stock on November 19, 2026. The reverse stock split aims to optimize the company's stock price as it continues to advance its clinical-stage pharmaceutical products, including MAR001 for severe hypertriglyceridemia and MAR002 for acromegaly.
Potential Positives
- The reverse stock split is aimed at increasing the per-share price of the common stock, which can help improve its market perception and attract new investors.
- The successful approval of the reverse stock split by stockholders indicates a favorable view of corporate governance and shareholder alignment.
- The reduction of issued shares from approximately 10.8 million to 0.7 million may enhance the value for existing shareholders by potentially decreasing the supply of shares in the market.
- Lisata Therapeutics is advancing clinical development of its product candidates, including MAR001 and MAR002, which could lead to significant medical advancements and commercial opportunities.
Potential Negatives
- The announcement of a one-for-fifteen reverse stock split may signal to investors that the company's stock price was not performing well, as reverse splits are often utilized to boost a declining stock price.
- The reduction in the number of shares from approximately 10.8 million to 0.7 million could lead to decreased liquidity and may make it harder for existing shareholders to sell their shares without affecting the stock price.
- The need for a reverse stock split raises concerns about the overall financial health and stability of the company, as such actions are typically viewed as a sign of underlying issues.
FAQ
What is the reverse stock split ratio for Lisata Therapeutics?
The reverse stock split ratio for Lisata Therapeutics is one-for-fifteen.
When will the reverse stock split take effect?
The reverse stock split will take effect on November 23, 2026.
What will the new CUSIP number be after the split?
The new CUSIP number for Lisata’s common stock will be 128058 401.
How many shares will be outstanding after the split?
The outstanding shares will reduce from approximately 10.8 million to approximately 0.7 million shares.
Will the reverse stock split affect ownership percentages?
The reverse stock split will not significantly affect stockholders' ownership percentages, aside from fractional share adjustments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LSTA Hedge Fund Activity
We have seen 20 institutional investors add shares of $LSTA stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,487,646 shares (+inf%) to their portfolio in Q3 2026, for an estimated $3,582,210
- TRV GP V, LLC added 455,192 shares (+inf%) to their portfolio in Q3 2026, for an estimated $655,476
- SEVEN FLEET CAPITAL MANAGEMENT LP added 371,411 shares (+inf%) to their portfolio in Q3 2026, for an estimated $534,831
- FCPM III SERVICES B.V. added 297,478 shares (+inf%) to their portfolio in Q3 2026, for an estimated $428,368
- ALPHA WAVE GLOBAL, LP added 183,323 shares (+inf%) to their portfolio in Q3 2026, for an estimated $263,985
- SOFINNOVA INVESTMENTS, INC. added 156,460 shares (+inf%) to their portfolio in Q3 2026, for an estimated $225,302
- VENBIO PARTNERS LLC added 156,460 shares (+inf%) to their portfolio in Q3 2026, for an estimated $225,302
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
LIBERTY CORNER, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ: LSTA) (“Lisata” or the “Company”) today announced a one-for-fifteen reverse stock split of its common stock. The Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the market open on November 23, 2026 under the existing trading symbol “LSTA”. The new CUSIP number for the Company’s common stock following the reverse stock split will be 128058 401.
At the Company’s 2026 annual meeting of stockholders held on November 9, 2026, the Company’s stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of its common stock at a ratio to be determined by the Company’s board of directors within the range from one-for-five to one-for-fifteen. The Company’s board of directors approved the reverse stock split at the ratio of one-for-fifteen.
At the effective time of the reverse stock split, every fifteen shares of the Company’s common stock then issued and outstanding will be combined into one share of common stock, without any change to the par value per share and without any change in the total number of authorized shares of common stock. The number of issued and outstanding shares of common stock will be reduced from approximately 10.8 million shares to approximately 0.7 million shares. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except for minor changes that may result from the treatment of fractional shares.
No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will receive a cash payment equal to the fractional share interest multiplied by the closing price of the Company’s common stock on The Nasdaq Capital Market on November 19, 2026, the date of the filing of the certificate of amendment to the Company’s amended and restated certificate of incorporation.
Outstanding securities or rights convertible into, or exchangeable or exercisable for, the Company’s common stock will be appropriately adjusted for the reverse stock split in accordance with their terms.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea Therapeutics, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The Company is also advancing MAR002 for the treatment of acromegaly. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. For more information on the Company, please visit www.lisata.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the effective date of the reverse stock split and date on which the Company’s common stock will begin trading on a split-adjusted basis. Words such as “expect,” “anticipate,” “plan,” “look forward” and similar expressions identify such statements. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.
Lisata
:
Investors and Media:
John Menditto
[email protected]